Menu
Search
|

Menu

Close
X

Aeterna Zentaris Inc AEZS.OQ (NASDAQ Stock Exchange Capital Market)

1.93 USD
+0.07 (+3.76%)
As of 9:42 PM IST
chart
Previous Close 1.86
Open 1.90
Volume 8,100
3m Avg Volume 106,681
Today’s High 1.93
Today’s Low 1.90
52 Week High 3.75
52 Week Low 0.78
Shares Outstanding (mil) 16.21
Market Capitalization (mil) 34.19
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
1
FY16
1
FY15
1
EPS (USD)
FY17
-1.104
FY16
-2.394
FY15
-35.303
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
31.75
5.77
Price to Book (MRQ)
vs sector
6.92
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-80.47
14.43
Return on Equity (TTM)
vs sector
-309.50
16.13

EXECUTIVE LEADERSHIP

Carolyn Egbert
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Michael Ward
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Jeffrey Whitnell
Interim Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Richard Sachse
Senior Vice President, Chief Scientific Officer, Chief Medical Officer, Since 2014
Salary: $222,000.00
Bonus: $55,500.00
Jude Dinges
Chief Commercial Officer, Senior Vice President, Since 2013
Salary: $320,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

315 Sigma Dr Ste 302D
SUMMERVILLE   SC   29486-7790

Phone: +1843.9003223

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

SPONSORED STORIES